Interferon-Beta Therapy Monitoring in Multiple Sclerosis Patients

E-ISSN： 2212-3873|9|1|14-28

ISSN： 1871-5303

Source： Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol.9, Iss.1, 2009-03, pp. : 14-28

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Interferon-beta Inhibits Th17 Cell Differentiation in Patients with Multiple Sclerosis

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 10, Iss. 2, 2010-06 ,pp. : 161-167

Bentham Science Publishers

Access to resources Recommend Favorite

Interferon-Beta in the Treatment of Multiple Sclerosis: Do Clinical Data Support the Existence of a Ceiling Effect?

By Clanet M.

Clinical Drug Investigation, Vol. 21, Iss. 4, 2001-04 ,pp. : 307-318

Adis International

Access to resources Recommend Favorite

Treating Relapsing Multiple Sclerosis with Subcutaneous versus Intramuscular Interferon-Beta-1a: Modelling the Clinical and Economic Implications

By Guo Shien Bozkaya Duygu

PharmacoEconomics, Vol. 27, Iss. 1, 2009-01 ,pp. : 39-53

Adis International

Access to resources Recommend Favorite

Improving Compliance with Interferon-β Therapy in Patients with Multiple Sclerosis

By Portaccio Emilio >

CNS Drugs, Vol. 23, Iss. 6, 2009-05 ,pp. : 453-462

Adis International

Access to resources Recommend Favorite

A Population Approach to Characterize Interferon Beta‐1b Effect on Contrast Enhancing Lesions in Patients With Relapsing Remitting Multiple Sclerosis

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 4, Iss. 5, 2015-05 ,pp. : 295-304

John Wiley & Sons Inc

Access to resources Recommend Favorite